Diffuse large B-cell lymphoma

Disease ID:1254
Name:Diffuse large B-cell lymphoma
Associated with:1 target
2 immuno-relevant ligands
Synonyms
DLBCL | DLBL
Description
DLBCL is an aggressive lymphoproliferative malignancy that arises in the lymph nodes. It is the most common subtype of non-Hodgkin lymphoma in adults. DLBCL is classified as a rare disease.
Database Links
Disease Ontology: DOID:0050745

Targets

CD37 molecule
Comments:  The anti-CD37 antibody conjugate naratuximab emtansine is an orphan drug that can be used in Europe and the US to treat patients with DLBCL.
Ligand interactions: 
Ligand Comments
naratuximab emtansine
Naratuximab emtansine is an EMA and FDA orphan drug that may be used to treat patients with DLBCL.
lilotomab
177Lu-lilotomab satetraxetan is a Phase 1 clinical candidate for relapsed/refractory DLBCL- see NCT02658968.

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
naratuximab emtansine 2-3
Immuno Disease Comments: Naratuximab emtansine is an EMA and FDA orphan drug that may be used to treat patients with DLBCL.
Clinical Use: Naratuximab emtansine (IMGN529) has completed Phase 1 clinical trial in patients with B cell malignancies (see NCT01534715) [4]. Naratuximab emtansine was granted EMA orphan designation for the treatment of diffuse large B cell lymphoma (DLBCL) in June 2015 [2], and by the FDA in May 2016 [3]. | View clinical data
Bioactivity Comments: The in vitro and in vivo (in NHL and CLL xenograft models) anti-tumour cell immune effector (intrinsic to the anti-CD37antibody) and anti-mitotic (due to the maytansinoid conjugate) activities of IMGN529 were reported by Deckert et al. in 2013 [1]. | View biological activity
lilotomab
Immuno Disease Comments: 177Lu-lilotomab satetraxetan is a Phase 1 clinical candidate for relapsed/refractory DLBCL- see NCT02658968.
Clinical Use: Click here to link to a complete list of lilotomab clinical studies that are registered at ClinicalTrials.gov. | View clinical data

References

Show »

1. Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, Mayo MF, Carrigan CN, Erickson HK, Pinkas J et al.. (2013) A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood, 122 (20): 3500-10. [PMID:24002446]

2. EMA. EU/3/15/1494 naratuximab emtansine orphan designation. Accessed on 11/05/2018. Modified on 11/05/2018. ema.europa.eu, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2015/06/human_orphan_001581.jsp&mid=WC0b01ac058001d12b

3. FDA. Naratuximab emtansine orphan designation. Accessed on 11/05/2018. Modified on 11/05/2018. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=518016

4. Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, Zucca E, Munteanu MC, Lia Palomba M. (2018) Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest New Drugs, 36 (5): 869-876. [PMID:29453628]